{"id":"somatostatin","rwe":[{"pmid":"41905933","year":"2026","title":"Effects of plant flavonoids and selenium on pancreatic hormones and glucose homeostasis in autoimmune thyroiditis.","finding":"","journal":"Experimental animals","studyType":"Clinical Study"},{"pmid":"41904067","year":"2026","title":"Resistant prolactinomas.","finding":"","journal":"Best practice & research. Clinical endocrinology & metabolism","studyType":"Clinical Study"},{"pmid":"41903538","year":"2026","title":"Alteration of cellular representation in the central amygdala mediates stress-induced analgesia in mice.","finding":"","journal":"Neuron","studyType":"Clinical Study"},{"pmid":"41895668","year":"2026","title":"Somatostatin-induced modulation of microglial activity contributes to mitigating Alzheimer's disease pathology.","finding":"","journal":"Brain, behavior, and immunity","studyType":"Clinical Study"},{"pmid":"41895270","year":"2026","title":"Circuit and molecular mechanisms underlying incubation of methamphetamine craving in the prelimbic cortex.","finding":"","journal":"Neuron","studyType":"Clinical Study"}],"tags":[{"label":"somatostatin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Somatostatin receptor type 2","category":"target"},{"label":"SSTR2","category":"gene"},{"label":"SSTR3","category":"gene"},{"label":"SSTR5","category":"gene"},{"label":"H01CB01","category":"atc"},{"label":"Active","category":"status"},{"label":"Hormones","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":64.964,"date":"","count":7,"signal":"Administration site abscess","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=65)"},{"llr":63.523,"date":"","count":7,"signal":"Administration site discharge","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=64)"},{"llr":62.193,"date":"","count":7,"signal":"Administration site odour","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=62)"},{"llr":62.059,"date":"","count":7,"signal":"Administration site induration","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=62)"},{"llr":55.672,"date":"","count":7,"signal":"Administration site haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=56)"},{"llr":55.272,"date":"","count":9,"signal":"Gastric varices","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=55)"},{"llr":54.37,"date":"","count":7,"signal":"Injection site cyst","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=54)"},{"llr":47.931,"date":"","count":7,"signal":"Buttock injury","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=48)"},{"llr":42.723,"date":"","count":7,"signal":"Injection site paraesthesia","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=43)"},{"llr":36.144,"date":"","count":6,"signal":"Carcinoid tumour","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=36)"},{"llr":36.125,"date":"","count":9,"signal":"Portal hypertension","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=36)"}],"commonSideEffects":[{"effect":"Administration site abscess","drugRate":"LLR 65","severity":"common"},{"effect":"Administration site discharge","drugRate":"LLR 64","severity":"common"},{"effect":"Administration site odour","drugRate":"LLR 62","severity":"common"},{"effect":"Administration site induration","drugRate":"LLR 62","severity":"common"},{"effect":"Administration site haemorrhage","drugRate":"LLR 56","severity":"common"},{"effect":"Gastric varices","drugRate":"LLR 55","severity":"common"},{"effect":"Injection site cyst","drugRate":"LLR 54","severity":"common"},{"effect":"Buttock injury","drugRate":"LLR 48","severity":"common"},{"effect":"Injection site paraesthesia","drugRate":"LLR 43","severity":"common"},{"effect":"Carcinoid tumour","drugRate":"LLR 36","severity":"common"},{"effect":"Portal hypertension","drugRate":"LLR 36","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"aminopan","offLabel":[],"synonyms":["somatostatin","aminopan","growth hormone release-inhibiting factor","somatotropin release-inhibiting hormone","SRIF-14"],"timeline":[],"approvals":[],"brandName":"Aminopan","ecosystem":[],"mechanism":{"target":"Somatostatin receptor type 1, Somatostatin receptor type 2, Somatostatin receptor type 3","targets":[{"gene":"SSTR2","source":"DrugCentral","target":"Somatostatin receptor type 2","protein":"Somatostatin receptor type 2"},{"gene":"SSTR3","source":"DrugCentral","target":"Somatostatin receptor type 3","protein":"Somatostatin receptor type 3"},{"gene":"SSTR5","source":"DrugCentral","target":"Somatostatin receptor type 5","protein":"Somatostatin receptor type 5"},{"gene":"SSTR1","source":"DrugCentral","target":"Somatostatin receptor type 1","protein":"Somatostatin receptor type 1"},{"gene":"SSTR4","source":"DrugCentral","target":"Somatostatin receptor type 4","protein":"Somatostatin receptor type 4"}],"modality":"Small Molecule","drugClass":"somatostatin","explanation":"Imagine your body has a 'brake' system that regulates the release of hormones and growth factors. Aminopan acts like a key that fits into this brake system, preventing the release of these substances and slowing down certain bodily processes.","oneSentence":"Aminopan works by binding to somatostatin receptors on cells, which blocks the release of hormones and growth factors.","technicalDetail":"Aminopan, a somatostatin analogue, exerts its effects through high-affinity binding to the somatostatin receptor type 2 (SSTR2), a G protein-coupled receptor, which inhibits adenylate cyclase activity and reduces the release of various hormones and growth factors."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2997","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SOMATOSTATIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SOMATOSTATIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:41:49.107028","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:40:49.737492+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"octreotide","drugSlug":"octreotide","fdaApproval":"1988-10-21","patentExpiry":"Sep 17, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lanreotide","drugSlug":"lanreotide","fdaApproval":"2007-08-30","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pasireotide","drugSlug":"pasireotide","fdaApproval":"2012-12-14","patentExpiry":"Oct 25, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"somatostatin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"octreotide","brandName":"octreotide","genericName":"octreotide","approvalYear":"1988","relationship":"same-class"},{"drugId":"lanreotide","brandName":"lanreotide","genericName":"lanreotide","approvalYear":"2007","relationship":"same-class"},{"drugId":"pasireotide","brandName":"pasireotide","genericName":"pasireotide","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":["Metastatic Pancreatic Neuroendocrine Tumor","Pancreatic Neoplasm","Stage III Pancreatic Neuroendocrine Tumor AJCC v8","Stage IV Pancreatic Neuroendocrine Tumor AJCC v8","Unresectable Pancreatic Neuroendocrine Tumor"],"enrollment":24,"completionDate":"2026-12-14"},{"nctId":"NCT05724108","phase":"PHASE2","title":"Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-30","conditions":["Metastatic Neuroendocrine Tumor"],"enrollment":94,"completionDate":"2026-12-09"},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":["Acromegaly"],"enrollment":119,"completionDate":"2029-03"},{"nctId":"NCT05477576","phase":"PHASE3","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-03-24","conditions":["GEP-NET","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Tumor Disease","Neuroendocrine Tumors","Carcinoid","Carcinoid Tumor","Pancreatic NET"],"enrollment":338,"completionDate":"2030-12"},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":["Advanced Lung Neuroendocrine Tumor","Functioning Lung Neuroendocrine Tumor","Locally Advanced Lung Neuroendocrine Neoplasm","Lung Neuroendocrine Neoplasm","Lung Neuroendocrine Tumor G1","Lung Neuroendocrine Tumor G2","Metastatic Lung Neuroendocrine Neoplasm","Metastatic Lung Neuroendocrine Tumor","Non-Functioning Lung Neuroendocrine Tumor","Recurrent Lung Neuroendocrine Neoplasm","Unresectable Lung Neuroendocrine Neoplasm","Unresectable Lung Neuroendocrine Tumor"],"enrollment":70,"completionDate":"2033-01-16"},{"nctId":"NCT04750954","phase":"PHASE1","title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-22","conditions":["Neuroendocrine Neoplasm"],"enrollment":29,"completionDate":"2026-06-30"},{"nctId":"NCT06991738","phase":"PHASE1,PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-02","conditions":["Thyroid Cancer"],"enrollment":18,"completionDate":"2032-08-01"},{"nctId":"NCT07037420","phase":"PHASE2","title":"ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-10-28","conditions":["Acromegaly"],"enrollment":60,"completionDate":"2027-11-11"},{"nctId":"NCT04727723","phase":"","title":"Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-03-09","conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":164,"completionDate":"2026-03-31"},{"nctId":"NCT04927416","phase":"PHASE2","title":"The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-10-25","conditions":["Metastic Thyroid Cancer"],"enrollment":54,"completionDate":"2030-11-30"},{"nctId":"NCT05361668","phase":"PHASE2","title":"Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2022-04-22","conditions":["Carcinoid Syndrome","Carcinoid","Carcinoid Tumor","Carcinoid Tumor of Ileum","Carcinoid Tumor of Cecum","Carcinoid Syndrome Diarrhea","Carcinoid Intestine Tumor","Carcinoid Tumor of Liver","Carcinoid Tumor of Pancreas"],"enrollment":36,"completionDate":"2026-02-24"},{"nctId":"NCT06590857","phase":"PHASE1,PHASE2","title":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","status":"ACTIVE_NOT_RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2024-07-19","conditions":["Metastatic Breast Cancer","HER2-negative Breast Cancer","ER+ Breast Cancer","Advanced Breast Cancer"],"enrollment":16,"completionDate":"2033-01"},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"enrollment":31,"completionDate":"2026-08-27"},{"nctId":"NCT07087054","phase":"PHASE3","title":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-11-19","conditions":["Carcinoid Syndrome","Carcinoid","Carcinoid Tumor","Carcinoid Tumor of Ileum","Carcinoid Tumor of Cecum","Carcinoid Tumor of Liver","Carcinoid Tumor of Pancreas","Carcinoid Syndrome Diarrhea","Carcinoid Intestine Tumor"],"enrollment":141,"completionDate":"2030-01"},{"nctId":"NCT06427798","phase":"PHASE1,PHASE2","title":"Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-07","conditions":["Somatostatin Receptor Positive","Gastrointestinal Neuroendocrine Tumors","Pheochromocytoma","Paragangliomas"],"enrollment":66,"completionDate":"2039-07-01"},{"nctId":"NCT07129252","phase":"PHASE1,PHASE2","title":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-11-26","conditions":["SST2-positive Neuroendocrine Neoplasms","Neuroendocrine Tumors","Neuroendocrine Neoplasm"],"enrollment":150,"completionDate":"2029-08"},{"nctId":"NCT05918302","phase":"PHASE3","title":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2023-10-27","conditions":["Neuroendocrine Tumors","Lung Neuroendocrine Neoplasm","Thymus Neoplasms"],"enrollment":120,"completionDate":"2028-07"},{"nctId":"NCT04837040","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly","status":"ACTIVE_NOT_RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2021-05-12","conditions":["Acromegaly"],"enrollment":58,"completionDate":"2027-06"},{"nctId":"NCT04298541","phase":"PHASE2","title":"Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-06","conditions":["Meningioma"],"enrollment":6,"completionDate":"2027-06"},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":["Pheochromocytoma","Paraganglioma","Neuroendocrine Tumors","Neuroendocrine Neoplasms"],"enrollment":130,"completionDate":"2033-01-01"},{"nctId":"NCT07413042","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-01-20","conditions":["SCLC, Extensive Stage"],"enrollment":24,"completionDate":"2028-06-30"},{"nctId":"NCT04711135","phase":"PHASE2","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2022-08-31","conditions":["Gastroenteropancreatic Neuroendocrine Tumors","Pheochromocytoma","Paraganglioma"],"enrollment":11,"completionDate":"2034-02-06"},{"nctId":"NCT06939036","phase":"PHASE1,PHASE2","title":"Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )","status":"TERMINATED","sponsor":"Ariceum Therapeutics GmbH","startDate":"2025-07-01","conditions":["Small Cell Lung Cancer Extensive Stage","Merkel Cell Carcinoma"],"enrollment":2,"completionDate":"2025-12-31"},{"nctId":"NCT07246421","phase":"NA","title":"Glucagon Resistance in Patients With MASLD and T2DM","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2026-01-29","conditions":["Metabolic Associated Fatty Liver Disease","Type 2 Diabetes (T2DM)"],"enrollment":24,"completionDate":"2028-07-31"},{"nctId":"NCT07366710","phase":"NA","title":"Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-05","conditions":["Glucose Metabolism","NAFLD (Nonalcoholic Fatty Liver Disease)"],"enrollment":36,"completionDate":"2027-10"},{"nctId":"NCT07350707","phase":"PHASE1,PHASE2","title":"Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-06-12","conditions":["Cushing s Syndrome"],"enrollment":160,"completionDate":"2027-02-12"},{"nctId":"NCT07304466","phase":"NA","title":"Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2025-12-29","conditions":["Liver Transplantation","Portal Hypertension"],"enrollment":50,"completionDate":"2027-03-30"},{"nctId":"NCT06416969","phase":"EARLY_PHASE1","title":"Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-01","conditions":["Obesity"],"enrollment":24,"completionDate":"2027-04-01"},{"nctId":"NCT03691064","phase":"","title":"Post-Authorization Long-Term Safety Study of LUTATHERA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2018-11-28","conditions":["Neuroendocrine Tumors"],"enrollment":1014,"completionDate":"2027-09-30"},{"nctId":"NCT04234568","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-20","conditions":["Metastatic Digestive System Neuroendocrine Neoplasm","Metastatic Neuroendocrine Tumor"],"enrollment":31,"completionDate":"2026-03-14"},{"nctId":"NCT07150806","phase":"PHASE1,PHASE2","title":"RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","status":"RECRUITING","sponsor":"Joshua Palmer","startDate":"2025-11-12","conditions":["Recurrent Meningioma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT05844332","phase":"","title":"LUTATHERA Injection General Use Result Survey","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":["Somatostatin Receptor-positive Neuroendocrine Tumor"],"enrollment":347,"completionDate":"2024-06-27"},{"nctId":"NCT02713776","phase":"PHASE2","title":"Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-12-13","conditions":["Enterostomy"],"enrollment":57,"completionDate":"2021-01-08"},{"nctId":"NCT06441331","phase":"PHASE1","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","status":"RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2025-09-26","conditions":["Somatostatin Receptor Positive","NETs","Lymphoma","Solid Tumor","CNS Tumors","Rhabdomyosarcoma","Peripheral Primitive Neuroectodermal Tumor","GIST"],"enrollment":20,"completionDate":"2034-04"},{"nctId":"NCT04086485","phase":"PHASE1,PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-03","conditions":["Gastroenteropancreatico Tumors","Neuroendocrine Tumors","Neuroendocrine Neoplasms"],"enrollment":56,"completionDate":"2028-01-01"},{"nctId":"NCT04069299","phase":"","title":"Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-25","conditions":["Neuroendocrine Carcinoma"],"enrollment":30,"completionDate":"2026-01"},{"nctId":"NCT02743741","phase":"NA","title":"Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2016-07-15","conditions":["Neuroendocrine Tumors"],"enrollment":195,"completionDate":"2026-06"},{"nctId":"NCT06840821","phase":"PHASE1,PHASE2","title":"Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors","status":"RECRUITING","sponsor":"Mainline Biosciences (Shanghai) Co., Ltd","startDate":"2025-05-08","conditions":["Advanced Solid Tumors"],"enrollment":156,"completionDate":"2028-07-04"},{"nctId":"NCT07252401","phase":"NA","title":"Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-12-25","conditions":["Liver Cirrhosis"],"enrollment":64,"completionDate":"2028-03-31"},{"nctId":"NCT06479811","phase":"PHASE1","title":"[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-19","conditions":["Head and Neck Tumors","Kidney Cancers","Small Cell Lung Cancers","Pheochromocytoma/Paragangliomas","Gastrointestinal Neuroendocrine Tumors","Somatostatin Receptor Positive"],"enrollment":120,"completionDate":"2032-01-01"},{"nctId":"NCT05178693","phase":"PHASE1","title":"Lutathera and ASTX727 in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2022-04-25","conditions":["Neuroendocrine Tumors"],"enrollment":27,"completionDate":"2029-02-28"},{"nctId":"NCT05636618","phase":"PHASE1,PHASE2","title":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Perspective Therapeutics","startDate":"2023-09-27","conditions":["Neuroendocrine Tumors Unresectable","Neuroendocrine Tumor Metastatic","Gastroenteropancreatic Neuroendocrine Tumor","Bronchial Neuroendocrine Tumor","Paraganglioma","Pheochromocytoma"],"enrollment":260,"completionDate":"2029-12-26"},{"nctId":"NCT06624631","phase":"PHASE4","title":"PDMC Implementation Trial in Kenya","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-05","conditions":["Severe Malaria","Severe Anemia"],"enrollment":600,"completionDate":"2026-09-30"},{"nctId":"NCT04081701","phase":"PHASE4","title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2019-09-04","conditions":["CNS Tumors","Meningioma","Esthesioneuroblastoma","Hemangioblastoma","Medulloblastoma","Paraganglioma","Pituitary Adenoma"],"enrollment":200,"completionDate":"2038-12-31"},{"nctId":"NCT03966651","phase":"PHASE1","title":"A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2023-04-17","conditions":["Neuroblastoma"],"enrollment":18,"completionDate":"2026-09"},{"nctId":"NCT07178938","phase":"PHASE2","title":"Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-04-30","conditions":["Solid Tumors","HER2-positive Breast Cancer"],"enrollment":10,"completionDate":"2028-12-31"},{"nctId":"NCT02270567","phase":"","title":"RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide","status":"ENROLLING_BY_INVITATION","sponsor":"Wren Laboratories LLC","startDate":"2015-02","conditions":["Neuroendocrine Tumor","Carcinoid","Neuroendocrine Carcinoma"],"enrollment":400,"completionDate":"2030-12"},{"nctId":"NCT05278208","phase":"PHASE1,PHASE2","title":"Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-21","conditions":["High Grade Glioma","Meningioma","Embryonal Tumor","Medulloblastoma","Anaplastic Ependymoma","Recurrent Diffuse Intrinsic Pontine Glioma","Recurrent Malignant Glioma","Recurrent Medulloblastoma","Recurrent Primary Central Nervous System Neoplasm","Refractory Diffuse Intrinsic Pontine Glioma","Refractory Malignant Glioma","Refractory Medulloblastoma","Refractory Primary Central Nervous System Neoplasm"],"enrollment":65,"completionDate":"2027-11"},{"nctId":"NCT02799212","phase":"PHASE3","title":"Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-01-10","conditions":["Hepatocellular Carcinoma"],"enrollment":179,"completionDate":"2024-04-30"},{"nctId":"NCT06982300","phase":"PHASE1,PHASE2","title":"SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-09-25","conditions":["Nasopharyngeal Carcinoma (NPC)"],"enrollment":10,"completionDate":"2026-12"},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":["Neuroblastoma","Pheochromocytoma","Paraganglioma"],"enrollment":30,"completionDate":"2028-06-30"},{"nctId":"NCT03000946","phase":"PHASE3","title":"Prevention of Postoperative Pancreatic Fistula by Somatostatin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-15","conditions":["Pancreatic Surgery"],"enrollment":655,"completionDate":"2021-02-09"},{"nctId":"NCT05387603","phase":"PHASE3","title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","status":"RECRUITING","sponsor":"Lund University Hospital","startDate":"2022-11-01","conditions":["Neuroendocrine Tumors"],"enrollment":300,"completionDate":"2026-10-01"},{"nctId":"NCT04919226","phase":"PHASE3","title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2021-12-21","conditions":["Neuroendocrine Tumors"],"enrollment":259,"completionDate":"2027-09"},{"nctId":"NCT07165132","phase":"PHASE1","title":"Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.","status":"NOT_YET_RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2025-10","conditions":["GEP-NET","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Tumor Disease","Neuroendocrine Tumors","Carcinoid","Carcinoid Tumor","Pancreatic NET","Solid Tumor","Somatostatin Receptor"],"enrollment":104,"completionDate":"2032-10"},{"nctId":"NCT04329039","phase":"PHASE2,PHASE3","title":"Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-11-17","conditions":["Pancreatic Diseases"],"enrollment":103,"completionDate":"2026-12-31"},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":["Neuroendocrine Tumors"],"enrollment":196,"completionDate":"2028-12"},{"nctId":"NCT06398444","phase":"PHASE2,PHASE3","title":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2024-06-11","conditions":["Advanced Neuroendocrine Neoplasm"],"enrollment":74,"completionDate":"2029-06-01"},{"nctId":"NCT03457948","phase":"PHASE2","title":"Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicholas Fidelman, MD","startDate":"2018-08-27","conditions":["Metastatic Malignant Neoplasm in the Liver","Neuroendocrine Neoplasm"],"enrollment":32,"completionDate":"2026-05-31"},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":["Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)"],"enrollment":166,"completionDate":"2029-01"},{"nctId":"NCT07138716","phase":"NA","title":"Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC","status":"RECRUITING","sponsor":"Luo Yaping","startDate":"2025-05-10","conditions":["Medullary Thyroid Carcinoma"],"enrollment":30,"completionDate":"2028-12-01"},{"nctId":"NCT06345079","phase":"PHASE2","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2024-10-14","conditions":["Neuroendocrine Tumors"],"enrollment":78,"completionDate":"2028-06"},{"nctId":"NCT05595460","phase":"PHASE1","title":"Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-10-10","conditions":["SCLC,Extensive Stage"],"enrollment":49,"completionDate":"2029-03"},{"nctId":"NCT01876771","phase":"PHASE2","title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2014-04-29","conditions":["Carcinoma, Neuroendocrine"],"enrollment":500,"completionDate":"2042-12"},{"nctId":"NCT01879657","phase":"NA","title":"68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)","status":"COMPLETED","sponsor":"Radio Isotope Therapy of America","startDate":"2013-03-01","conditions":["Neuroendocrine Carcinoma"],"enrollment":169,"completionDate":"2017-12-05"},{"nctId":"NCT03241706","phase":"PHASE1","title":"Liver Glycogen and Hypoglycemia in Humans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jason Winnick","startDate":"2018-08-02","conditions":["Hypoglycemia; Iatrogenic"],"enrollment":40,"completionDate":"2028-05-31"},{"nctId":"NCT02678780","phase":"PHASE2","title":"Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2015-10","conditions":["Neuroendocrine Tumors"],"enrollment":123,"completionDate":"2020-08"},{"nctId":"NCT04837885","phase":"PHASE2","title":"Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-24","conditions":["Neuroendocrine Tumor","Liver Metastases","Neuroendocrine Gastroenteropancreatic Tumour"],"enrollment":23,"completionDate":"2027-03-24"},{"nctId":"NCT06395402","phase":"PHASE2","title":"177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry","status":"RECRUITING","sponsor":"University of Iowa","startDate":"2024-05-03","conditions":["Neuroendocrine Tumors","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2"],"enrollment":120,"completionDate":"2029-12-31"},{"nctId":"NCT07064746","phase":"","title":"Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-07-10","conditions":["Neuroblastoma (NB)"],"enrollment":150,"completionDate":"2027-07-10"},{"nctId":"NCT05581550","phase":"NA","title":"Somatostatin Receptor Imaging in NPC, EBV Related Cancers","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2020-06-29","conditions":["Nasopharyngeal Cancer","Epstein-Barr Virus Related Carcinoma"],"enrollment":15,"completionDate":"2025-07-17"},{"nctId":"NCT05111509","phase":"EARLY_PHASE1","title":"A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yusuf Menda","startDate":"2022-08-22","conditions":["Neuroendocrine Tumor Grade 2","Neuroendocrine Tumor Grade 1"],"enrollment":20,"completionDate":"2026-06-30"},{"nctId":"NCT06632860","phase":"EARLY_PHASE1","title":"A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-01","conditions":["Iodine-resistant Thyroid Cancer","Meningioma","NETs"],"enrollment":40,"completionDate":"2025-12-30"},{"nctId":"NCT06732505","phase":"PHASE1","title":"A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-09-29","conditions":["Neuroendocrine Neoplasm"],"enrollment":36,"completionDate":"2026-03-31"},{"nctId":"NCT07012330","phase":"PHASE2","title":"Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2007-03-01","conditions":["Neuroendocrine (NE) Tumors"],"enrollment":111,"completionDate":"2015-12-31"},{"nctId":"NCT03466216","phase":"PHASE1","title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","status":"TERMINATED","sponsor":"Orano Med LLC","startDate":"2018-02-05","conditions":["Neuroendocrine Tumor"],"enrollment":33,"completionDate":"2023-04-06"},{"nctId":"NCT06255249","phase":"","title":"Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-10-30","conditions":["Meningioma"],"enrollment":50,"completionDate":"2025-03-30"},{"nctId":"NCT05153772","phase":"PHASE2","title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orano Med LLC","startDate":"2021-12-21","conditions":["Neuroendocrine Tumors"],"enrollment":69,"completionDate":"2028-10"},{"nctId":"NCT06091748","phase":"PHASE3","title":"Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-02-22","conditions":["Advanced Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":66,"completionDate":"2025-11-01"},{"nctId":"NCT06455358","phase":"PHASE1,PHASE2","title":"61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-02-05","conditions":["Neuroendocrine Tumors"],"enrollment":27,"completionDate":"2028-06"},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":["Neuroendocrine Tumors"],"enrollment":309,"completionDate":"2029-11"},{"nctId":"NCT06372652","phase":"PHASE1","title":"A Phase 1 Study of TE-8214 Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Immunwork, Inc.","startDate":"2024-06-18","conditions":["Acromegaly"],"enrollment":32,"completionDate":"2024-12-06"},{"nctId":"NCT06974344","phase":"PHASE4","title":"Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)","status":"NOT_YET_RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2025-06-01","conditions":["Small-for-Size Syndrome"],"enrollment":80,"completionDate":"2030-09-01"},{"nctId":"NCT03145857","phase":"PHASE1,PHASE2","title":"A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2020-03-05","conditions":["Neuroendocrine Tumors"],"enrollment":1534,"completionDate":"2046-08"},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":["Neuroendocrine Tumors"],"enrollment":51,"completionDate":"2023-04-10"},{"nctId":"NCT04888481","phase":"PHASE2","title":"68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-02-15","conditions":["Neuroendocrine Tumors"],"enrollment":600,"completionDate":"2028-08-31"},{"nctId":"NCT04544098","phase":"EARLY_PHASE1","title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":["Neuroendocrine Tumors","Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors"],"enrollment":10,"completionDate":"2026-09"},{"nctId":"NCT04997317","phase":"PHASE1,PHASE2","title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-21","conditions":["Meningioma"],"enrollment":18,"completionDate":"2026-12-31"},{"nctId":"NCT04464122","phase":"","title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","status":"RECRUITING","sponsor":"University of Roma La Sapienza","startDate":"2020-09-14","conditions":["Neuroendocrine Tumors","Neuroendocrine Neoplasm","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Carcinoma"],"enrollment":60,"completionDate":"2025-12-31"},{"nctId":"NCT03631173","phase":"NA","title":"Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2019-04-02","conditions":["Pancreatic Cancer","Pancreatic Neoplasms","Biliary Tract Cancer","Duodenal Cancer","Pancreatic Fistula"],"enrollment":201,"completionDate":"2026-07-31"},{"nctId":"NCT05249114","phase":"PHASE1","title":"Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-12-28","conditions":["Neuroendocrine Tumors"],"enrollment":6,"completionDate":"2026-12"},{"nctId":"NCT06611891","phase":"PHASE3","title":"Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2025-01-06","conditions":["Breast Cancer Metastatic"],"enrollment":25,"completionDate":"2026-10"},{"nctId":"NCT06855095","phase":"PHASE2,PHASE3","title":"Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-06-25","conditions":["Neuroendocrine Tumors","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Neoplasm"],"enrollment":39,"completionDate":"2027-03-01"},{"nctId":"NCT02795858","phase":"PHASE2","title":"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-06-14","conditions":["Carcinoid Tumors"],"enrollment":43,"completionDate":"2023-12-31"},{"nctId":"NCT06830356","phase":"NA","title":"Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas.","status":"RECRUITING","sponsor":"Centro di Riferimento Oncologico - Aviano","startDate":"2024-12-23","conditions":["Meningioma"],"enrollment":53,"completionDate":"2037-12-23"},{"nctId":"NCT03789656","phase":"PHASE2","title":"An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2019-03-12","conditions":["Acromegaly"],"enrollment":47,"completionDate":"2020-08-31"},{"nctId":"NCT02778425","phase":"NA","title":"The Treatment of Hepatocirrhosis and Portal Hypertension","status":"COMPLETED","sponsor":"Yanjing Gao","startDate":"2016-02","conditions":["Hepatic Cirrhosis","Portal Hypertension"],"enrollment":108,"completionDate":"2020-01"},{"nctId":"NCT01371045","phase":"","title":"Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2011-06","conditions":["Acromegaly"],"enrollment":0,"completionDate":"2019-06"},{"nctId":"NCT06690957","phase":"","title":"Somatostatin Receptor PET/CT in SSTR-Related Disease Patients","status":"RECRUITING","sponsor":"Tianjin Medical University","startDate":"2019-02-01","conditions":["SSTR-related Disease","Tumor","Positron Emission Tomography","Metastasis"],"enrollment":500,"completionDate":"2027-10-01"},{"nctId":"NCT05680675","phase":"NA","title":"Dual-Tracer Theranostic PET","status":"COMPLETED","sponsor":"University of Utah","startDate":"2022-12-08","conditions":["Neuroendocrine Tumors","Prostate Cancer"],"enrollment":50,"completionDate":"2024-06-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000007997","NDDF":"005072","UNII":"6E20216Q0L","CHEBI":"CHEBI:64628","INN_ID":"4311","RXNORM":"9939","UMLSCUI":"C0037659","ChEMBL_ID":"CHEMBL1823872","KEGG_DRUG":"D07431","DRUGBANK_ID":"DB09099","PUBCHEM_CID":"16129706","SNOMEDCT_US":"49722008","IUPHAR_LIGAND_ID":"2019","MESH_DESCRIPTOR_UI":"D013004"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":34752,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"H01CB01","allCodes":["H01CB01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 30","pmid":"41905933","title":"Effects of plant flavonoids and selenium on pancreatic hormones and glucose homeostasis in autoimmune thyroiditis.","journal":"Experimental animals"},{"date":"2026 Mar 24","pmid":"41904067","title":"Resistant prolactinomas.","journal":"Best practice & research. Clinical endocrinology & metabolism"},{"date":"2026 Mar 27","pmid":"41903538","title":"Alteration of cellular representation in the central amygdala mediates stress-induced analgesia in mice.","journal":"Neuron"},{"date":"2026 Mar 25","pmid":"41895668","title":"Somatostatin-induced modulation of microglial activity contributes to mitigating Alzheimer's disease pathology.","journal":"Brain, behavior, and immunity"},{"date":"2026 Mar 26","pmid":"41895270","title":"Circuit and molecular mechanisms underlying incubation of methamphetamine craving in the prelimbic cortex.","journal":"Neuron"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"","aiSummary":"Aminopan is a small molecule. Its exact clinical uses and mechanism of action are not specified in the provided information.","enrichmentLevel":5,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":6,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:40:49.737492+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}